Navigation Links
ULURU Inc. Signs Offer Letter to Acquire York Pharma plc
Date:4/6/2009

ADDISON, Texas, April 6 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Amex: ULU) today announced that it has signed a non-binding offer letter to acquire York Pharma plc ("York"). York is a United Kingdom based skin care company with operations or distribution networks throughout Europe with an established revenue base.

One of the conditions to ULURU making any offer is that the outstanding debt of York (currently being U.S. $6 million of unsecured Convertible Loan Notes 2014, together with accrued interest thereon) shall be converted into ordinary shares of York prior to the closing of any offer. Under the indicative terms set out in the non-binding offer letter, ULURU shareholders would own approximately 77% of the combined company. York shareholders (as enlarged by the conversion of the outstanding debt) would own approximately 23% of the combined company, which would result in ULURU issuing approximately 19.9 million shares.

In conjunction with the signing of the non-binding offer letter, ULURU entered into a series of agreements involving the granting of a revolving line of credit to York. As security for advances made against this line of credit ULURU received a security interest in substantially all of the assets of York.

ULURU and York have not executed definitive documentation relating to any acquisition transaction. There can be no assurance that the parties will enter into definitive documentation for such an acquisition transaction.

ULURU is pursuing a potential acquisition as strategically this is important and would be expected to provide the following benefits to ULURU:

  • Significantly enhance the commercial capability of the Company by creating an integrated U.S. and European marketing and sales infrastructure
  • Afford the ability to leverage the existing sales and marketing organizations
  • Create a larger company with an established revenue base providing an effective vehicle to more rapidly grow both internally and from selected product acquisitions
  • Enhance the profile of the Company better positioning us to be a partner of choice for skin care licensing and product acquisition opportunities
  • Better positions the Company to attract capital market support from both U.S. and European institutions
  • Offers the potential to more rapidly drive growth in shareholder value
  • Offers the potential for significant administrative synergy savings

Commenting on the potential acquisition, Renaat Van den Hooff, President and CEO of ULURU stated, "The potential benefits to be derived from this proposed acquisition will significantly accelerate the maturation of ULURU into a commercially based company with a strong revenue base. This revenue base will positively position the company for more rapid growth both in the United States and Europe."

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers with improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex(TM) Aggregate technology and transmucosal delivery system. For more information about Altrazeal(TM), please visit www.Altrazeal.com. For more information about ULURU Inc., please visit www.uluruinc.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including statements relating to the possible acquisition of York by the Company and statements relating to potential strategic benefits of any such acquisition. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and other reports filed by us with the Securities and Exchange Commission.

    Contact: Company
    Renaat E. Van den Hooff
    President & CEO
    Terry K. Wallberg
    Vice President & CFO
    (214) 905-5145


'/>"/>
SOURCE ULURU Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ULURU Inc. to Present at UBS Global Life Sciences Conference 2007
2. ULURU Inc. Announces Odd-Lot Buy Back Offer
3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2007 and Provide a Business Update
4. ULURU Inc. Reports Third Quarter 2007 Results
5. ULURU Inc. Announces Issuance of Notice of Allowance for Nanoparticle Aggregate Patent
6. ULURU Inc. to Present at Cowen and Company 28th Annual Health Care Conference 2008
7. ULURU Inc. Announces Conference Call to Discuss Financial Results for the First Quarter Ended March 31, 2008 and Provide a Business Update
8. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter Ended December 31, 2007 and Provide a Business Update
9. ULURU Inc. Announces the Launch Plan for Altrazeal(TM)
10. ULURU Inc. Reports First Quarter 2008 Financial Results
11. ULURU Inc. Announces the Appointment of Ronald A. Ahrens to the Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... , ... April 26, 2017 ... ... provides an agile ecosystem and domain expertise for sponsors and CROs to ... and trial supply management (RTSM) software platform. Bioclinica AGILE RTSM ...
(Date:4/25/2017)... San Jose, CA (PRWEB) , ... April 25, ... ... in cross-screen access, support, and collaboration, announces Mirroring360 Pro . This new ... providing a comprehensive collaboration experience for education and business. , Mirroring360 Pro enables ...
(Date:4/25/2017)... ... ... A stressful work environment can hurt the physical and emotional health of employees. ... workplace. The goal of Clearview Resolution Services has always been to help others, starting ... will be shutting down the office early on Fridays. The Clearview team will use ...
(Date:4/25/2017)... ... 25, 2017 , ... The doctors at Wall Centre Dental are now expanding ... and require sedation to receive dental care. The doctors offer three treatment options to ... cleanings to oral surgery, at their dental office in Vancouver. Wall Centre Dental is ...
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical ... partners to help with process innovation in drug formulation and manufacturing. CoreRx ... with state-of-the-art analytical equipment in support of their development and manufacturing goals. ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the highest market ... segment is likely to create absolute $ opportunity of a ... By the end of 2027, Cardiology Devices segment is projected ... expanding at a CAGR of 18.4% over the forecast period. ... reprocessed medical devices market in terms of revenue ...
(Date:4/19/2017)...  IRIDEX Corporation (Nasdaq: IRIX ) today ... first quarter 2017 after the close of trading on ... host a corresponding conference call beginning at 2:30 p.m. ... in listening to the conference call may do so ... 326-3030 for international callers, using conference ID: 92158987.  A ...
(Date:4/19/2017)... Global Prostate Cancer Therapeutics Market: Overview ... cancer therapeutics market analyzes the current and future ... prostate cancer, launch of promising emerging therapies, as ... drugs & therapeutic biological products, and high growth ... side effects are some of the drivers expected ...
Breaking Medicine Technology: